The Medical Advisor

Executive Summary Cancer is no longer best understood purely as a genetic disease. By 2026, a growing body of research supports a more integrated model: cancer as a metabolic, immunologic, and microenvironmental disorder . This report presents a unified framework: Cancer is a dysregulated adaptive system driven by metabolic flexibility, immune evasion, and microenvironmental control. Key insights: Tumors rely on three dominant fuels : glucose, glutamine, and lactate Mitochondrial dysfunction is central to cancer progression and stemness The tumor microenvironment (TME) actively suppresses immune response Metabolic therapies may enhance—not replace—standard treatments Combination strategies outperform single-agent approaches. Introduction: A Broader View of Cancer Biology Traditional oncology often focuses on genetic mutations and targeted therapies. While mutations are critical, emerging research shows that cancer is also a disease of metabolic dysfunction and immu...

Executive Summary Dr. Thomas N. Seyfried , Professor of Biology at Boston College, proposes a metabolic model of cancer that challenges the dominant genetic explanation and conventional oncology treatments. Rather than viewing cancer as primarily driven by gene mutations, Seyfried asserts it is fundamentally a metabolic disease centered on dysfunctional cellular energy production. This reframing draws on and expands the historical Warburg effect , emphasizing how cancer cells rely on fermentative metabolism of glucose and glutamine due to defective mitochondrial function.  A 2026 large-scale population study published in Nature Communications demonstrated that machine learning-predicted insulin resistance was associated with increased risk of 12 cancer types in nearly 500,000 individuals from the UK Biobank. This finding strengthens a growing thesis: Metabolic dysfunction is not merely a comorbidity — it may be a central modifiable axis in oncogenesis. Standard of Care: T...